| Literature DB >> 26229962 |
Yuan Xu1, Qiang Wang2, Yudong Li3, Yibo Gan3, Pei Li3, Songtao Li3, Yue Zhou4, Qiang Zhou3.
Abstract
Different loading regimens of cyclic tensile strain impose different effects on cell proliferation and tenogenic differentiation of TDSCs in three-dimensional (3D) culture in vitro, which has been little reported in previous literatures. In this study we assessed the efficacy of TDSCs in a poly(L-lactide-co-ε-caprolactone)/collagen (P(LLA-CL)/Col) scaffold under mechanical stimulation in the custom-designed 3D tensile bioreactor, which revealed that cyclic tensile strain with different frequencies (0.3 Hz, 0.5 Hz, and 1.0 Hz) and amplitudes (2%, 4%, and 8%) had no influence on TDSC viability, while it had different effects on the proliferation and the expression of type I collagen, tenascin-C, tenomodulin, and scleraxis of TDSCs, which was most obvious at 0.5 Hz frequency with the same amplitude and at 4% amplitude with the same frequency. Moreover, signaling pathway from microarray analysis revealed that reduced extracellular matrix (ECM) receptor interaction signaling initiated the tendon genius switch. Cyclic tensile strain highly upregulated genes encoding regulators of NPM1 and COPS5 transcriptional activities as well as MYC related transcriptional factors, which contributed to cell proliferation and differentiation. In particular, the transcriptome analysis provided certain new insights on the molecular and signaling networks for TDSCs loaded in these conditions.Entities:
Mesh:
Year: 2015 PMID: 26229962 PMCID: PMC4502284 DOI: 10.1155/2015/790804
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Real-time PCR primers used in this study. Primers for type I collagen, tenascin-C, tenomodulin, and scleraxis and GAPDH were designed and synthesized by Sangon Biotech Co., Ltd.
| Gene | Sequence | |
|---|---|---|
| Type I collagen | Forward | 5′ tcagaacatcacctaccactgc 3′ |
| Reverse | 5′ attgtctttccccattcatttg 3′ | |
|
| ||
| Tenascin-C | Forward | 5′ atcaccaccaagttcacaacag 3′ |
| Reverse | 5′ ccatccacagattcatagagca 3′ | |
|
| ||
| Tenomodulin | Forward | 5′ tccacaattcggcataatc 3′ |
| Reverse | 5′ caggtccgggattctgtgt 3′ | |
|
| ||
| Scleraxis | Forward | 5′ ccacaccaagcattttcaga 3′ |
| Reverse | 5′acacaaaggacggcatcac 3′ | |
|
| ||
| GAPDH | Forward | 5′ atggtgaaggtcggagtgaa 3′ |
| Reverse | 5′ tgggtggaatcatactggaac 3′ | |
Figure 1LSCM images of TDSCs on the scaffolds stained by Live/Dead assays and analysis on the proportion of the number of living cells in the total number of cells for each group. (a) Control group. (b)–(j) Experimental groups 1–9. (k) There was no statistical difference in the proportion of the number of living cells in the total number of cells between experimental groups and control group (P > 0.05, n = 3) (in all images, scale = 100 μm).
Figure 2WST-1 results of TDSCs cultured in control group and different experimental groups (1 d for (a); 3 d for (b); 5 d for (c); 7 d for (d)). The data were expressed as mean ± SD. The samples indicated with asterisk (∗) had a significant difference between experimental groups and control group (P < 0.05) (n = 3).
Figure 3Expression of type I collagen (a), tenascin-C (b), tenomodulin (c), and scleraxis (d) of TDSCs cultured in control group and different experimental groups for 7 days. The expression levels, quantified using real-time RT-PCR, were normalized to those of housekeeping gene (GADPH). TDSCs in the control group served as controls (the expression levels of tendon ECM genes were treated as 1 in this group). The data were expressed as mean ± SD. The samples indicated with asterisk (∗) had a significant difference between experimental groups and control group (P < 0.05) (n = 3).
Figure 4Transcriptome microarray analysis of TDSCs in the stimulated groups (a-1 and a-2) and control groups (c-1 and c-2), calculated with cluster 3.0.
The top 20 upregulated and downregulated genes with cyclic tensile strain or not.
| Fold change | Gene symbol | Gene description |
|---|---|---|
| 9.32 | Tppp3 | Tubulin polymerization-promoting protein family member 3 |
| 5.38 | Rrad | Ras-related associated with diabetes |
| 5.31 | Aass | Aminoadipate-semialdehyde synthase |
| 5.2 | Elmod1 | ELMO/CED-12 domain containing 1 |
| 4.88 | Crabp2 | Cellular retinoic acid binding protein 2 |
| 4.65 | S100a5 | S100 calcium binding protein A5 |
| 4.44 | Gjb3 | Gap junction protein, beta 3 |
| 4.2 | Kcnn4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 3.98 | Mthfs | 5,10-Methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclo-ligase) |
| 3.97 | Lmo1 | LIM domain only 1 |
| 3.83 | Cxcl10 | Chemokine (C-X-C motif) ligand 10 |
| 3.8 | S100a10 | S100 calcium binding protein A10 |
| 3.78 | Anxa8 | Annexin A8 |
| 3.73 | Tspan2 | Tetraspanin 2 |
| 3.68 | Ezr | Ezrin |
| 3.66 | Crip1 | Cysteine-rich protein 1 (intestinal) |
| 3.58 | Mlf1ip | Myeloid leukemia factor 1 interacting protein |
| 3.54 | Clec2dl1 | C-type lectin domain family 2 member D-like 1 |
| 3.53 | Fam111a | Family with sequence similarity 111, member A |
| 3.38 | Atp2b4 | ATPase, Ca++ transporting, plasma membrane 4 |
|
| ||
| 0.12 | IGF-1 | Insulin-like growth factor 1 |
| 0.14 | Stc1 | Stanniocalcin 1 |
| 0.16 | Olr1 | Oxidized low density lipoprotein (lectin-like) receptor 1 |
| 0.17 | Nkd2 | Naked cuticle homolog 2 ( |
| 0.18 | Lpl | Lipoprotein lipase |
| 0.18 | Rgs16 | Regulator of G-protein signaling 16 |
| 0.19 | LOC24906 | RoBo-1 |
| 0.19 | Slc15a3 | Solute carrier family 15, member 3 |
| 0.2 | Kbtbd10 | Kelch repeat and BTB (POZ) domain containing 10 |
| 0.21 | Rgs2 | Regulator of G-protein signaling 2 |
| 0.22 | RGD1308023 | Similar to CG5521-PA |
| 0.23 | RGD1308023 | Similar to CG5521-PA |
| 0.23 | RGD1308023 | Similar to CG5521-PA |
| 0.24 | Bmp4 | Bone morphogenetic protein 4 |
| 0.24 | Ibsp | Integrin-binding sialoprotein |
| 0.24 | Kcnj2 | Potassium inwardly rectifying channel, subfamily J, member 2 |
| 0.24 | Lmcd1 | LIM and cysteine-rich domains 1 |
| 0.25 | Agtr1a | Angiotensin II receptor, type 1a |
| 0.25 | Avpr1a | Arginine vasopressin receptor 1A |
| 0.25 | Fat4 | FAT tumor suppressor homolog 4 ( |
KEGG signaling pathways associated with transcriptome expression differences between the cyclic tensile strain and no treatment.
| Term | Count | % |
| Genes |
|---|---|---|---|---|
| rno03030: DNA replication | 21 | 2.341137124 | 1.00 | LIG1, POLE, MCM2, POLA2, MCM3, LOC317415, RNASEH2B, MCM4, MCM5, MCM6, RPA3, PRIM1, RFC5, RPA2, MCM7, RFC4, RFC2, POLE3, POLD2, PRIM2, PCNA, FEN1 |
|
| ||||
| rno04110: cell cycle | 34 | 3.790412486 | 9.83 | E2F1, E2F5, DBF4, TTK, CHEK1, CHEK2, CCNE2, CCNE1, CDKN2A, MCM7, BUB1, MYC, CCNA2, BUB3, CDC6, RBL1, ESPL1, CDC20, CDK6, MCM2, CDC25C, MCM3, LOC317415, MCM4, MCM5, ATM, SMC3, MCM6, CCNB1, CCND1, MAD2L1, CCNB2, PLK1, PCNA, BUB1B |
|
| ||||
| rno03050: proteasome | 18 | 2.006688963 | 1.27 | PSMB10, PSMB4, PSMB7, PSMC6, PSMD14, PSMB6, PSMC5, PSMA6, PSMC4, PSMB1, PSMA5, PSME2, PSMA4, PSMB3, PSMC1, PSMA3, POMP, PSMD6 |
|
| ||||
| rno00240: pyrimidine metabolism | 20 | 2.229654404 | 1.06 | POLR3G, POLR1E, CTPS, POLE, POLR1A, POLR1C, CAD, POLA2, POLR3D, PRIM1, TYMS, UMPS, NME2, POLE3, NT5C3, RRM2, POLD2, PRIM2, UCK2, DUT |
|
| ||||
| rno03430: mismatch repair | 10 | 1.114827202 | 5.35 | EXO1, RFC5, RPA2, RFC4, RFC2, MSH2, LIG1, POLD2, PCNA, RPA3 |
|
| ||||
| rno04115: p53 signaling pathway | 15 | 1.672240803 | 3.77 | BID, STEAP3, CDK6, CHEK1, CHEK2, ATM, GTSE1, CCNE2, CCNB1, CCNE1, CCND1, CASP3, CDKN2A, CCNB2, RRM2 |
|
| ||||
| rno03420: nucleotide excision repair | 11 | 1.226309922 | 4.08 | RFC5, RPA2, RFC4, POLE3, RFC2, LIG1, POLE, POLD2, PCNA, ERCC1, RPA3 |
|
| ||||
| rno00230: purine metabolism | 21 | 2.341137124 | 8.38 | POLR3G, POLR1E, NUDT5, POLE, POLR1A, POLR1C, POLA2, PPAT, GART, POLR3D, PRIM1, NME2, POLE3, ATIC, NT5C3, RRM2, ADK, POLD2, PRIM2, PRPS2, PRPS1 |
|
| ||||
| rno00670: one carbon pool by folate | 6 | 0.668896321 | 6.33 | MTHFD1, MTHFS, TYMS, DHFR, ATIC, GART |
|
| ||||
| rno03440: homologous recombination | 7 | 0.780379041 | 0.001556012 | RPA2, NBN, POLD2, BRCA2, RAD54L, RPA3, RAD51 |
|
| ||||
| rno03410: base excision repair | 8 | 0.891861761 | 0.002577441 | POLE3, NEIL3, LIG1, POLE, POLD2, PCNA, APEX1, FEN1 |
|
| ||||
| rno04114: oocyte meiosis | 14 | 1.560758082 | 0.003751587 | PPP2R1B, SGOL1, ESPL1, CDC20, CDC25C, SMC3, CCNB1, CCNE2, CCNE1, MAD2L1, CCNB2, PLK1, BUB1, FBXO5 |
|
| ||||
| rno00270: cysteine and methionine metabolism | 7 | 0.780379041 | 0.00748193 | GOT1, AHCY, DNMT1, AHCYL2, AMD1, APIP, SMS |
|
| ||||
| rno05322: systemic lupus erythematosus | 11 | 1.226309922 | 0.014926373 | HIST1H2BA, HIST1H2BB, HIST1H2BH, SSB, LOC682330, LOC680498, HIST1H2BM, HIST1H4B, HIST2H2AC, HIST1H2AI, HIST3H2A, H2AFX, HIST1H2AO |
|
| ||||
| rno03040: spliceosome | 13 | 1.449275362 | 0.018817601 | PRPF31, PPIL1, EFTUD2, MAGOH, SNRPB2, CWC15, SNRPD2, SF3B2, PRPF19, PLRG1, THOC4, LSM3, SNRPF |
|
| ||||
| rno00480: glutathione metabolism | 7 | 0.780379041 | 0.039033496 | LAP3, ODC1, GSTA2, GSTA4, RRM2, SMS, GCLM |
|
| ||||
| rno03020: RNA polymerase | 5 | 0.557413601 | 0.039888482 | POLR3G, POLR1E, POLR1A, POLR1C, POLR3D |
|
| ||||
| rno04512: ECM-receptor interaction | 16 | 2.285714286 | 7.51 | IBSP, COL4A2, ITGA1, ITGA11, LAMA2, LAMA4, LAMB2, LAMA5, ITGB8, ITGA7, TNN, AGRN, LAMC1, COL11A1, THBS2, THBS4 |
|
| ||||
| rno04510: focal adhesion | 24 | 3.428571429 | 3.96 | IBSP, COL4A2, VAV3, ITGA11, ITGA1, IGF1, HGF, MYL9, LAMA2, LAMA4, LAMB2, LAMA5, ITGB8, ITGA7, PDGFRA, PDGFRB, TNN, LAMC1, EGF, COL11A1, FIGF, THBS2, SHC4, THBS4 |
|
| ||||
| rno05414: dilated cardiomyopathy | 11 | 1.571428571 | 0.003630871 | LAMA2, ADCY4, ITGB8, ITGA7, ADCY6, ITGA11, ITGA1, IGF1, CACNB3, CACNA1C, SGCB |
|
| ||||
| rno04270: vascular smooth muscle contraction | 12 | 1.714285714 | 0.00645965 | RAMP3, ADCY4, AGTR1A, ADORA2A, PPP1R12B, ADCY6, AVPR1A, NPR2, PRKG1, CACNA1C, PRKCE, MYL9 |
|
| ||||
| rno00230: purine metabolism | 14 | 2 | 0.010450898 | ADCY4, ENPP3, ADCY6, PDE10A, PDE3A, NPR2, PDE4D, AMPD3, POLD4, PDE7B, PDE4B, ENTPD4, ENTPD1, ENTPD2 |
|
| ||||
| rno05410: hypertrophic cardiomyopathy (HCM) | 9 | 1.285714286 | 0.02148213 | LAMA2, ITGB8, ITGA7, ITGA11, ITGA1, IGF1, CACNB3, CACNA1C, SGCB |
|
| ||||
| rno05412: arrhythmogenic right ventricular cardiomyopathy (ARVC) | 8 | 1.142857143 | 0.031599478 | LAMA2, ITGB8, ITGA7, ITGA11, ITGA1, CACNB3, CACNA1C, SGCB |
|
| ||||
| rno04614: renin-angiotensin system | 4 | 0.571428571 | 0.046740741 | AGTR1A, MME, ANPEP, ENPEP |
Figure 5Ingenuity interactome analysis of the effect of cyclic tensile strain-affected gene expression was performed using the Ingenuity software. The gene products in network were displayed as nodes, and the biological relationships between the nodes were displayed as lines. Different shapes represented different functional classes of gene products. The color of each node indicates the degree of upregulation (red) or downregulation (green) of the respective gene transcript. Network 1: the COPS5 and NPM1 network connected with several important canonical pathways, which shows the connection of this network to DNA replication.
Figure 6MYC signaling. MYC as a hub of connectivity appeared to play a central role possessing 30 targeted genes via direct connections.